Limba
|
Tirbanibulin, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50of 9-60 nM in cancer cell lines. Phase 2.
| Price | 992,00 RON (preturile sunt fara TVA) |
|---|---|
| Description |
Tirbanibulin, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50of 9-60 nM in cancer cell lines. Phase 2. |